Contineum Therapeutics, Inc.
CTNM
$14.19
-$1.11-7.26%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -4.83% | 4.62% | -18.48% | 20.25% | -0.31% |
| Total Depreciation and Amortization | 61.45% | -2.35% | 4.94% | 2.53% | 1.28% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -13.42% | 46.88% | -1.64% | 25.60% | -13.48% |
| Change in Net Operating Assets | 100.15% | -713.54% | 68.11% | -18.51% | -78.74% |
| Cash from Operations | 29.29% | -24.72% | -6.93% | 22.12% | -8.67% |
| Capital Expenditure | 98.08% | -642.86% | 57.14% | -122.73% | 6.38% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 112.46% | 17.75% | -415.25% | 7.98% | -6.91% |
| Cash from Investing | 112.35% | 17.16% | -417.60% | 7.61% | -6.91% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 532.83% | -99.79% | 387.18% | 7,085.39% | 1,012.50% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 23.19% | -- | 100.00% | 54.55% | -- |
| Cash from Financing | 830.23% | -99.86% | 389.22% | 20,894.51% | 279.17% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 90.18% | -268.17% | 50.90% | 1,395.91% | -419.92% |